Santen and UBE received FDA approval for Omlonti
EMERYVILLE, Cali. — Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) announced Monday that the U.S. Food and Drug Administration (FDA) has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
